...
首页> 外文期刊>Biomacromolecules >Fabrication of Reductive-Responsive Prodrug Nanoparticles with Superior Structural Stability by Polymerization-Induced Self-Assembly and Functional Nanoscopic Platform for Drug Delivery
【24h】

Fabrication of Reductive-Responsive Prodrug Nanoparticles with Superior Structural Stability by Polymerization-Induced Self-Assembly and Functional Nanoscopic Platform for Drug Delivery

机译:聚合诱导的自组装和功能性纳米平台用于药物传递的具有结构稳定性的还原反应前药纳米粒子的制备。

获取原文
获取原文并翻译 | 示例
           

摘要

A highly efficient strategy, polymerization induced self-assembly (PISA) for fabrication of the polymeric drug delivery systems in cancer chemotherapy is reported. Diblock prodrug copolymer, PEG-b-P(MEO(2)MA-co-CPTM) was used as the macro-RAFT agent to fabricate prodrug nanoparticles through PISA. The advantages of fabricating intelligent drug delivery system via this approach are as following: (1) Simultaneous fulfillment of polymerization, self assembly, and drug encapsulation in one-pot at relatively high concentration (100 mg/mL); (2) Almost complete monomer conversion allows direct application of the resultant prodrug nanoparticles without further purification; (3) Robust structures of the resultant prodrug nanoparticles, because the cross-linker was used as the comonomer, resulted in core-cross-linking simultaneously with the formation of the prodrug nanoparticles; (4) The drug content in the resultant prodrug nanoparticles can be accurately modulated just via adjusting the feed molar ratio of MEO(2)MA/CPTM in the synthesis of PEG-b-P(MEO(2)MA-co-CPTM). The prodrug nanoparticles with similar diameters but various drug contents were obtained using different prodrug macro-CTA. In consideration of the long-term biological toxicity, the prodrug nanoparticles with higher drug content exhibit more excellent anticancer efficiency due to that lower dosage of them are enough for effectively killing HeLa cells.
机译:据报道,一种用于在癌症化疗中制造聚合物药物递送系统的聚合诱导自组装(PISA)高效策略。使用双嵌段前药共聚物PEG-b-P(MEO(2)MA-co-CPTM)作为大分子RAFT剂,以通过PISA制备前药纳米颗粒。通过这种方法制造智能药物输送系统的优点如下:(1)在一个锅中以相对较高的浓度(100 mg / mL)同时完成聚合,自组装和药物封装; (2)几乎完全的单体转化允许直接应用所得的前药纳米颗粒而无需进一步纯化; (3)由于使用交联剂作为共聚单体,因此所得到的前药纳米颗粒具有稳固的结构,从而在前药纳米颗粒形成的同时导致了核交联。 (4)仅通过调节PEG-b-P(MEO(2)MA-co-CPTM)合成中MEO(2)MA / CPTM的进料摩尔比,就可以准确地调节所得前药纳米颗粒中的药物含量。使用不同的前药大分子CTA可获得直径相似但药物含量不同的前药纳米颗粒。考虑到长期的生物毒性,具有较高药物含量的前药纳米颗粒由于具有较低的剂量足以有效杀死HeLa细胞而具有更优异的抗癌效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号